Cite
HARVARD Citation
Wynne, C. et al. (2022). A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert opinion on investigational drugs. pp. 965-976. [Online].